Skip to content
DataLookout
Menu

ZEBRHA 3NCT07838194

Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change.

  1. Notable Recruitment opened
    • Study sites: 0 to 1
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Annualized Bleed Rate (ABR) for Treated Bleeds Over the Main Study Treatment Period
Timeframe: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)

Secondary (18)

ABR for All Bleeds Over the Main Study Treatment Period
ABR for Treated Spontaneous Bleeds Over the Main Study Treatment Period
ABR for Treated Joint Bleeds Over the Main Study Treatment Period
ABR for Treated Target Joint Bleeds Over the Main Study Treatment Period
Percentage of Participants with Zero Treated Bleeds Over the Main Study Treatment Period
Show 13 moreShow less
Number of Injections and Dose per Bleed of Factor VIII or Bypassing Agent Administered to Treat a Bleed Over the Main Study Treatment Period
Annualized Injection Rate of FVIII or Bypassing Agent Over the Main Study Treatment Period
Annualized Consumption Rate of FVIII or Bypassing Agent Over the Main Study Treatment Period
Change from Baseline in the Treatment Burden Domain Score on the Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) 2.0 Caregiver Questionnaire at Month 8
Change from Baseline in the Preoccupation Domain Score on the CATCH 2.0 Caregiver Questionnaire at Month 8
Incidence and Severity of Adverse Events, With Severity Determined According To National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0 Grading Scale
Incidence and Severity of Thromboembolic Events and Thrombotic Microangiopathy
Incidence and Severity of Injection-Site Reactions
Incidence of Adverse Events Leading to Study Drug Discontinuation
Incidence of Severe Hypersensitivity, Anaphylaxis, or Anaphylactoid Reactions
Plasma Concentrations of NXT007
Percentage of Participants With Anti-Drug Antibodies (ADAs) Against NXT007 at Baseline and During the Study
Percentage of Participants With Neutralizing ADAs Against NXT007

Arms and interventions

NXT007 ProphylaxisExperimental

Drugs: NXT007

Sites

1 site in 1 country

  • St. Marianna University HospitalKawasaki-Shi, Kanagawa, Japan